TrivarX Limited (AU:TRI)
ASX:TRI
Top Page
TrivarX Limited
(Sydney:TRI)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.02
▲(0.00% Upside)
Action:ReiteratedDate:04/11/26
The score is primarily held back by weak financial performance (ongoing losses and negative operating/free cash flow), with only partial support from a low-leverage balance sheet. Technical indicators are mixed but lean weak (negative MACD and sub-50 RSI), and valuation is difficult to justify given the negative P/E and absence of dividend yield data.
Positive Factors
Low Leverage Balance Sheet
The company’s very low debt-to-equity and a ~12.65M equity base materially reduce financial distress risk and provide a capital cushion. This durable strength increases flexibility to fund operations, endure further product development, or access non-dilutive financing over months.
Negative Factors
Persistent Unprofitability
Consecutive multi-year net losses and negative EBITDA/EBIT indicate the core business is not yet generating operating profits. Sustained unprofitability limits internal capital formation, increases reliance on external funding, and raises execution and dilution risk if profitability is not achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage Balance Sheet
The company’s very low debt-to-equity and a ~12.65M equity base materially reduce financial distress risk and provide a capital cushion. This durable strength increases flexibility to fund operations, endure further product development, or access non-dilutive financing over months.
Read all positive factors
TrivarX Limited (TRI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$23.07M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)2.80
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TrivarX Limited Business Overview & Revenue Model
Company Description
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-bein...
TrivarX Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2024 | Jun 2023 |
|---|---|---|
Income Statement | ||
| Total Revenue | 0.00 | 0.00 |
| Gross Profit | -52.47K | 0.00 |
| EBITDA | -1.89M | -1.13M |
| Net Income | -943.23K | -1.24M |
Balance Sheet | ||
| Total Assets | 13.48M | 10.81M |
| Cash, Cash Equivalents and Short-Term Investments | 1.25M | 848.10K |
| Total Debt | 169.03K | 15.90K |
| Total Liabilities | 831.22K | 1.18M |
| Stockholders Equity | 12.65M | 9.88M |
Cash Flow | ||
| Free Cash Flow | -189.74K | -3.70M |
| Operating Cash Flow | -189.74K | 0.00 |
| Investing Cash Flow | -2.09M | -2.85M |
| Financing Cash Flow | 2.68M | 4.32M |
TrivarX Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$19.56M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
46 Neutral | AU$14.30M | -2.48 | -578.72% | ― | 241.34% | 44.19% | |
45 Neutral | AU$23.07M | -11.02 | -7.84% | ― | ― | ― | |
43 Neutral | AU$31.35M | -3.13 | -1009.84% | ― | 25.98% | 22.10% | |
42 Neutral | AU$11.47M | -0.80 | -137.16% | ― | -48.41% | -7200.00% | |
40 Underperform | AU$13.96M | -1.71 | -1122.02% | ― | -67.78% | 37.78% |
* Healthcare Sector Average
AU:TRI
TrivarX Limited
0.02
<0.01
81.82%
AU:RHT
Resonance Health Ltd
0.04
0.00
0.00%
AU:PKY
Opyl Ltd.
0.02
0.00
0.00%
AU:AHE
MedAdvisor Limited
0.02
-0.07
-80.00%
AU:ICR
InteliCare Holdings Limited
0.02
0.01
130.00%
AU:PCK
PainChek Ltd
0.15
-0.18
-54.41%
TrivarX Limited Corporate Events
TrivarX reshapes leadership and governance to drive digital health commercialisation
Mar 4, 2026
TrivarX has terminated the employment of Chief Medical Officer Dr Archie Defillo, who played a key role in developing its MEB-001 and single-channel ECG algorithms, as the company shifts toward a more commercially focused phase. To drive this tran...
TrivarX Flags Sharp Revenue Fall and Wider Loss as Auditor Raises Going-Concern Uncertainty
Feb 24, 2026
TrivarX Limited reported a collapse in revenue from ordinary activities to $2,270 for the half-year ended 31 December 2025, compared with $1.13 million a year earlier, while its net loss attributable to members widened sharply to $1.26 million fro...
TrivarX Expands into Brain Cancer Imaging as Veteran Trial Validates Depression Diagnostic
Jan 29, 2026
TrivarX has exercised its option to acquire 100% of the Stabl-Im brain imaging intellectual property from Nucleics Pty Ltd, expanding its portfolio beyond ECG-based diagnostics into neuro-oncology. Stabl-Im is designed to use stable isotope labell...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.